4 Articles
4 Articles
Saint Louis – According to a study published in BMJ, therapy with GLP-1 receptor agonists (GLP-1 RAs) is associated with a lower risk of new-onset substance use disorders (SUDs) compared to SGLT2 inhibitors (2026; DOI: 10.1136/bmj-2025-086886). According to the team led by Miao Cai from the VA Saint Louis Health Care System, this suggests...
Could GLP‑1 drugs help treat addiction?
Emerging evidence points to a potential role, but questions remain Recent observational studies and early clinical signals suggest that glucagon‑like peptide‑1 (GLP‑1) receptor agonists — medicines widely used for type 2 diabetes and, more recently, for obesity — may reduce the risk of developing…
Coverage Details
Bias Distribution
- 100% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium


